HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
4-oxo-5-phosphononorvaline
structure given in first source; competitive glutamate antagonist at the NMDA receptor complex; RN given refers to (R)-isomer
Also Known As:
4-OPNV; MDL 100453; MDL-100,453
Networked:
2
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Amino Acids: 30675
Branched-Chain Amino Acids: 2289
Valine: 1999
4-oxo-5-phosphononorvaline: 2
Essential Amino Acids: 1152
Valine: 1999
4-oxo-5-phosphononorvaline: 2
Related Diseases
1.
Infarction (Infarctions)
06/01/1996 - "
A statistically significant (p < 0.05), but poor inverse correlation existed between the average blood level of MDL-100,453 and infarct volume.
"
06/01/1994 - "
Moreover, a statistically significant inverse correlation was demonstrated between the infarct volume and blood levels of MDL-100,453 at 60 minutes and 120 minutes after injection (r = -.33 and r = -.49, respectively).
"
06/01/1994 - "
Infarct volume of animals that received the MDL-100,453 bolus injection followed by MDL-100,453 infusion was significantly smaller than that of controls (P < .01).
"
06/01/1996 - "
Administration of a competitive NMDA antagonist MDL-100,453 reduces infarct size after permanent middle cerebral artery occlusion in rat.
"
06/01/1994 - "
The competitive NMDA antagonist MDL-100,453 reduces infarct size after experimental stroke.
"
2.
Stroke (Strokes)
06/01/1994 - "
The competitive NMDA antagonist MDL-100,453 reduces infarct size after experimental stroke.
"
3.
Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
06/01/1996 - "
Administration of a competitive NMDA antagonist MDL-100,453 reduces infarct size after permanent middle cerebral artery occlusion in rat.
"
4.
Ischemia
06/01/1994 - "
We demonstrated a significant neuroprotective effect of MDL-100,453 when treatment was initiated 30 minutes after ischemia began and was maintained for 24 hours.
"
06/01/1994 - "
The competitive N-methyl-D-aspartate antagonist MDL-100,453 was used to determine whether a neuroprotective effect is demonstrable when the drug is administered beginning 30 minutes after the initiation of focal ischemia and whether the effect is related to blood levels of the drug.
"
5.
Brain Ischemia (Cerebral Ischemia)
06/01/1996 - "
We demonstrated that a short-term (9 h) intravenous administration of an appropriate dose of MDL-100,453 beginning 30 min after MCAO significantly reduces ischemic lesion volume at 24 h after onset of permanent focal cerebral ischemia.
"
06/01/1996 - "
The competitive N-methyl-D-aspartate antagonist MDL-100,453 has been shown to attenuate ischemic cell damage when administered after permanent focal cerebral ischemia.
"
Related Drugs and Biologics
1.
N-Methylaspartate (NMDA)
2.
Neuroprotective Agents
Related Therapies and Procedures
1.
Intravenous Administration